Exicure reveals positive data from XCUR17 clinical trial for Psoriasis
Category: #health  By Pankaj Singh  Date: 2019-10-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Exicure reveals positive data from XCUR17 clinical trial for Psoriasis

Clinical trials play a vital role in developing new treatments that could immensely improve a person’s living. Today, researchers and pharmaceutical company are working hard for making breakthroughs in psoriasis treatments.

Exicure Inc. is one such gene-regulating and immunomodulatory drug developer who has recently announced positive clinical results from its drug candidate XCUR17 in psoriasis at the 15th Annual Meeting of the OTS (Oligonucleotide Therapeutics Society) held in Munich.

Reportedly, Dr. David Giljohann, Chief Executive Officer, Exicure, presented the clinical data of XCUR17 at the session of Oligonucleotides Clinical Studies.

Sources close to the study claim that all enrolled patients received daily application of three strengths of XCUR17 vehicle gel and gel to different affected skin areas for twenty-five days. Biopsies were collected from the affected areas following 25-days of treatment as well as from lesional and nonlesional skin at baseline.

Clinical findings related with psoriasis-linked markers and histological variations from biopsies offered by patients showed that in the XCUR17 treatment:

  • There was a decrease in the levels of inflammation markers downstream and psoriasis of XCUR17's target, IL-17RA.
  • There was a substantial decrease in keratin 16 expression which is a key marker of psoriasis.
  • There was a reduction in the major inflammatory markers interleukin 36A, beta-defensin 4A and interleukin 19, versus psoriatic skin at baseline.
  • It showed clinical improvements that matched decreases in epidermal thickness and keratin 16 protein.

Prior to these attained outcomes, on 17 December 2018, Exicure had announced top-line results from Phase 1 trial assessing XCUR17 in patients who has mild-to-moderate chronic plaque psoriasis.

At that time, the highest strength XCUR17 gel indicated a statistically meaningful improvement in psoriasis affected skin. Such findings from the Phase 1 trial showed that SNA-based drugs like XCUR17 may use effectively in treating psoriasis.

Source Credit - https://www.businesswire.com/news/home/20191016005268/en/Exicure-Presents-Positive-Biomarker-Results-Clinical-Trial



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...